USA - NYSE:AVNS - US05350V1061 - Common Stock
The current stock price of AVNS is 11.43 USD. In the past month the price decreased by -0.09%. In the past year, price decreased by -38.91%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 24.37 | 36.78B | ||
| COO | COOPER COS INC/THE | 17.31 | 13.83B | ||
| SOLV | SOLVENTUM CORP | 11.48 | 12.10B | ||
| ALGN | ALIGN TECHNOLOGY INC | 13.64 | 9.56B | ||
| BLCO | BAUSCH + LOMB CORP | 35.98 | 5.48B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 22.24 | 4.82B | ||
| LNTH | LANTHEUS HOLDINGS INC | 8.74 | 3.80B | ||
| ICUI | ICU MEDICAL INC | 15.65 | 2.91B | ||
| XRAY | DENTSPLY SIRONA INC | 7.52 | 2.57B | ||
| HAE | HAEMONETICS CORP/MASS | 10.63 | 2.38B | ||
| ESTA | ESTABLISHMENT LABS HOLDINGS | N/A | 1.51B | ||
| UFPT | UFP TECHNOLOGIES INC | 21.94 | 1.46B |
Avanos Medical, Inc. is a medical technology company, which engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company is headquartered in Alpharetta, Georgia and currently employs 2,227 full-time employees. The company went IPO on 2014-10-21. The company offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. The company also includes TKO, an anti-reflux needleless connector technology, which is used in Neonatal and Pediatric Intensive Care Units. The Pain Management and Recovery portfolio of products includes surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems and Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.
AVANOS MEDICAL INC
5405 Windward Parkway, Suite 100 South
Alpharetta GEORGIA 30004 US
CEO: Joseph F. Woody
Employees: 2227
Phone: 18444282667
Avanos Medical, Inc. is a medical technology company, which engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company is headquartered in Alpharetta, Georgia and currently employs 2,227 full-time employees. The company went IPO on 2014-10-21. The company offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. The company also includes TKO, an anti-reflux needleless connector technology, which is used in Neonatal and Pediatric Intensive Care Units. The Pain Management and Recovery portfolio of products includes surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems and Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.
The current stock price of AVNS is 11.43 USD. The price decreased by -1.3% in the last trading session.
AVNS does not pay a dividend.
AVNS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
6 analysts have analysed AVNS and the average price target is 17.34 USD. This implies a price increase of 51.71% is expected in the next year compared to the current price of 11.43.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AVNS.
AVANOS MEDICAL INC (AVNS) has a market capitalization of 530.35M USD. This makes AVNS a Small Cap stock.
ChartMill assigns a fundamental rating of 4 / 10 to AVNS. AVNS has an average financial health and profitability rating.
Over the last trailing twelve months AVNS reported a non-GAAP Earnings per Share(EPS) of 1.21. The EPS decreased by -0.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.58% | ||
| ROE | -59.67% | ||
| Debt/Equity | 0.12 |
6 analysts have analysed AVNS and the average price target is 17.34 USD. This implies a price increase of 51.71% is expected in the next year compared to the current price of 11.43.
For the next year, analysts expect an EPS growth of -35.56% and a revenue growth -1.38% for AVNS